Rafael Holdings (RFL) risk factors
Item 1A of every Rafael Holdings, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors70 risks11 new17 dropped22 reworded
The risk section reflects Rafael Holdings' completed merger with Cyclo, shifting focus to Trappsol Cyclo's clinical trials and manufacturing. Financial disclosures now show post-merger cash of $52.8 million and material control weaknesses. Risks from regional conflict in Israel and new tariffs have been added.
Filed Oct 29, 2025 - FY2024 10-K risk factors76 risks
Rafael Holdings faces high risk from its reliance on early-stage clinical trials, including the pending merger with Cyclo and its Phase III trial for Trappsol Cyclo. The company holds limited cash and liquid assets totaling roughly $68.5 million while burning capital on unproven drug and medical device candidates. Extensive regulatory hurdles, third-party dependencies, and intense competitive threats across biopharma and real estate leasing threaten commercial success.
Filed Nov 07, 2024